General Atlantic Service Company, L.P. / General Atlantic
General Atlantic leads Expedition Therapeutics $115 million Series B
Summary: A General Atlantic-hosted release says Expedition Therapeutics announced an oversubscribed $115 million Series B financing led by General Atlantic. The release says Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, will join Expedition's board.
Why it matters: The update may matter to due-diligence readers as a public growth-equity and life-sciences deployment signal for General Atlantic, while it should not be read as evidence of clinical success, regulatory approval, valuation, fund performance, future returns, or investment merit.
Summary
A General Atlantic-hosted release says Expedition Therapeutics announced an oversubscribed $115 million Series B financing led by General Atlantic. The release says RA Capital, Vivo Capital, and existing investors participated, and that Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, will join Expedition’s board.
The release says proceeds will support EXPD-101 Phase 2 development and pipeline work. This article treats those clinical-stage and use-of-proceeds details as source-attributed background, not as evidence of clinical efficacy, regulatory likelihood, company valuation, investment outcome, or future returns.
Why it matters
For due-diligence readers, the useful signal is General Atlantic’s named lead role and board participation in a life-sciences financing. It can help readers track where the manager is publicly active by sector, stage, governance role, and specialist team involvement.
The signal is bounded. A manager-hosted financing announcement supports the financing amount, named participants, lead-investor role, board appointment, and source-described use of proceeds. It does not establish clinical success, drug approval, patient outcomes, valuation reasonableness, fund performance, investor demand, suitability, or investment merit.
Source notes
- General Atlantic-hosted announcement: https://www.generalatlantic.com/media-article/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/
- Source posture: primary manager-hosted press release with accessible body-level support.
- Verifier support: cleared for drafting with high manager-identity confidence, support for General Atlantic’s lead role and Brett Zbar board appointment, and no same-event local duplicate found for Expedition / General Atlantic.
- Editorial caveat: keep clinical, trial, and pipeline language short and attributed to the source. Do not imply 9AT has assessed efficacy, approval likelihood, or commercial potential.
9AT filing context
Public filing/profile context reviewed by 9AT maps General Atlantic Service Company, L.P. to a New York registered-adviser platform associated with generalatlantic.com, CRD 133536 and SEC file 801-63864. The reviewed context summarized about $125.3 billion in reported ADV regulatory AUM/profile scale, about $124.3 billion in total private-fund gross asset value across 449 private funds, 881 employees, 411 advisory employees, separately managed account activity, and a latest profile submission date of March 31, 2026.
That context is broad platform identity support only. It should not be used to identify the Expedition investing vehicle, board-seat source, financing economics, investor demand, valuation, clinical prospects, fund performance, or future returns. General Atlantic’s broad 13F footprint and Form 5500 plan records do not explain this private financing and are intentionally omitted as substantive evidence.
What to watch
Watch for General Atlantic, Expedition Therapeutics, regulatory, clinical-trial, or company materials that clarify financing close details, board composition, development milestones, use-of-proceeds updates, or later changes in General Atlantic’s involvement. Future coverage should keep life-sciences and clinical-stage claims tied to public source language and avoid converting financing participation into an investment or clinical conclusion.